AnaptysBio’s ANB020 has sound IL-33 MOA for Phase II peanut allergy efficacy but need for long-term safety data - experts
AnaptysBio’s (NASDAQ:ANAB) Phase II study with its anti-IL33 antibody ANB020 has encouraging preclinical data offering a sound rationale for Phase II efficacy, experts said. However, long-term safety data in humans will be needed to allay major concerns, they added.
Some analysts have noted the ‘blockbuster potential’ ANB020 could make potentially USD 2.8bn in 2027, but others have also pointed out that it is lagging in development compared to Phase III competitors from Aimmune Therapeutics (NASDAQ:AIMT) and DBV Technologies(NASDAQ:DBVT).
ANB020, AnaptysBio’s lead candidate, is an antibody to IL-33, a pro-inflammatory cytokine that has been implicated as a central mediator in food allergies, atopic dermatitis and asthma. Anti-IL33 research for food-based allergies has thus far been largely restricted to animal studies, giving experts pause in estimating its potential success in humans. However, optimism prevails due to the establishing role of IL-33 as an initiator in the cascade that leads to anaphylactic reactions. Analysts have found the Phase I pharmacokinetic data satisfactory and consistent with other antibodies.